Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for prevention and treatment of postpartum depression after cesarean delivery
ChiCTR2200064860Phase 4Recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine in postpartum depression (PPD) (5 arms), sponsored by Xi'an International Medical Center Hospital. Primary endpoint: Edinburgh Postnatal Depression Scale. Started Apr 2022; status: recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ChiCTR2200064860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064860.